Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire New Injectable Medicine Manufacturing Facility of Nexus Pharmaceuticals, Inc. on April 22, 2024. As part of the transaction, Weil, Gotshal & Manges LLP is acting as legal advisor to Eli Lilly and Company. Centerview Partners LLC is acting as financial advisor, and Sullivan & Cromwell LLP as legal advisor to Nexus Pharmaceuticals, Inc.